1p19q codeletion

1p19q codeletion stands for the combined loss of the short arm chromosome 1 (i.e. 1p) and the long arm of chromosome 19 (19q) and is recognised as a genetic marker predictive of therapeutic response to both chemotherapy and combined chemoradiotherapy and overall longer survival in patients with diffuse gliomas, especially those with oligodendroglial components 1-2, 4

Historically, the 1p19q codeletion was present in up to 70-85% of oligodendrogliomas and 50% of oligoastrocytomas 1,4. The recent (2016) revision to the WHO classification of CNS tumours has highlighted the importance of 1p19q codeletion by making it essential for the diagnosis of oligodendroglioma (along with the IDH mutation). 

In other words: 

When the IDH is negative, it corresponds to the ‘wild type’ and the tumour behaves far more aggressively, with a poor prognosis, similar to that of primary glioblastoma (GBM) 3. This is discussed further in the article on IDH

Astrocytic tumour
Share article

Article information

rID: 39164
Section: Pathology
Tag: cases
Synonyms or Alternate Spellings:
  • 1p-19q codeletion
  • 1p/19q codeletion
  • 1p/19q chromosome loss
  • 1p-19q chromosome loss

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    WHO 2016 diffuse glioma classification
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.